Yields Crashed. Stocks Recovered. The Reason Behind Both Is Uncomfortable.

The S&P closed higher after three straight down sessions. The Nasdaq gained modestly. The Dow added slightly. Yields fell sharply after Treasury doubled its bond buyback program. The 30-year yield dropped from 5.33% to 5.197% in one session.

Gold surged to its highest level since early June. Bitcoin jumped to $68K. The healthcare sector hit an all-time high. Those three things do not usually move together. They moved together today because Bessent's buyback announcement weakened the dollar, sent yields lower, and lifted everything that benefits when real rates fall.

Then the Fed minutes landed. Hawkish. The relief was real. The problem underneath it is also real.

TQ Trade Implication

Treasury bought the market a single session of relief. The minutes confirmed the Fed still wants to hike if inflation holds. Both are true at the same time. Position for volatility, not direction.

Bessent Doubled Bond Buybacks. Critics Say It Changes Nothing Structurally.

Treasury Secretary Bessent announced the government would at least double its bond buyback operations for 10-, 20- and 30-year debt, from $2 billion to at least $4 billion per operation. Yields crashed immediately. The 30-year dropped nearly 9 basis points. Stocks rallied. Gold surged.

Then the criticism arrived. The WSJ's Heard on the Street was direct: the July federal deficit alone was $432 billion. Buying back $4 billion in bonds per operation is a rounding error. The only way to actually lower long-term yields is either deficit reduction or Fed yield curve control. Neither is politically available right now.

Jim Bianco called it best: "Bond traders can stop panicking when Bessent starts panicking." The move worked today. It worked because it signaled the administration is watching. Whether that signal holds next week is a different question.

TQ Execution Bias

The buyback bought one session. The next 30-year auction will tell you if it bought anything more. Watch Thursday's bid-to-cover ratio. A weak auction reverses today's entire yield move.

Moderna More Than Doubled. mRNA Just Proved It Can Fight Cancer Too.

Moderna (MRNA) surged more than 140% after it and Merck (MRK) announced their experimental mRNA-based cancer vaccine succeeded in a late-stage trial for high-risk melanoma. Merck jumped 12%. The S&P healthcare sector hit an all-time closing high. BioNTech (BNTX) rose 20%. Roche gained nearly 2%. The entire biotech ETF jumped 5%.

This matters far beyond one drug. Moderna's stock collapsed after COVID-era optimism faded. mRNA became politically toxic and scientifically doubted. Today's trial result is the clearest evidence yet that mRNA works outside of infectious disease. The technology that billions dismissed as a one-trick pandemic tool just delivered a positive late-stage cancer result.

Roughly 13.7% of Moderna's float was sold short going into this. That short squeeze amplified a genuine scientific result into a 140% move.

TQ Execution Bias

Own the mRNA platform broadly. BioNTech has colorectal and pancreatic cancer programs still in pipeline. Today's trial validates the mechanism, not just one company.

The Fed Minutes Said What Nobody Wanted to Read.

"Many participants assessed that policy tightening would likely be necessary if inflation did not decline." That is the Fed's July meeting minutes. Three dissenters voted to hike at that meeting. Some officials separately said financial conditions may not be restrictive enough.

The Treasury buyback sent yields lower this morning. The Fed minutes confirmed the committee is still leaning toward hikes this afternoon. Both events happened on the same day. The yield market moved lower on one and should have moved higher on the other. It chose to focus on Bessent.

The minutes land while yields were already at 19-year highs. The dissenters have not changed their view. If inflation does not cool in the next CPI print, they have the language to push again.

TQ Edge Setup

The Fed minutes confirm September is not off the table despite markets pricing just a 32% chance of a hike. Watch next month's CPI as the actual decision variable.

• Bitcoin hit $68,000, up nearly 6%, as crypto company leaders met with President Trump at the White House. Coinbase (COIN) jumped 10%. Strategy (MSTR) gained 12%. American Bitcoin surged 17%. The White House meeting is the most direct political signal to the crypto sector since the regulatory framework passed last year.
• The US and Canada are close to finalizing a trade deal that would cut steel and aluminum tariffs from 50% to 25% and auto tariffs from 25% to 15%. Trump delayed threatened 50% levies by three days Tuesday night. Canadian metals names moved on the news. So did US auto stocks.
• OpenAI's Q2 revenue grew 18% from Q1 but disappointed investors as losses deepened simultaneously. That compares to Anthropic's 14x year-over-year growth. Oracle (ORCL) fell on the OpenAI news. Broadcom (AVGO) and AMD (AMD) shed around 4%.

Treasury blinked. Yields fell.

Moderna tripled on a cancer vaccine. The Fed confirmed it still wants to hike. Bitcoin hit $68K. Gold hit an 11-week high. The S&P broke its three-day losing streak.

The buyback bought a session. The Fed minutes bought uncertainty. Tomorrow Walmart (WMT) reports before the open. It is the most comprehensive single read on the American consumer that exists. Whatever Walmart says about the second half is the number the entire retail and inflation trade has to live inside.